Clinical trials: Decompensated Cirrhosis of Liver
Cirrhosis
Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis
The standard treatment for decompensated cirrhosis is liver transplantation, however, it has several limitations. Recent animal studies suggest that bone marrow stem cell transplantation can lead to regression of liver fibrosis.
- Trial name
- NCT00476060
- Testing
- Autologous mesenchymal stem cell transplantation
- Where
- Iran
- Volunteers
- 27 people
- Sponsor
- University of Tehran
Decompensated Cirrhosis and Ascites
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in participants…
- Trial name
- PRECIOSA (NCT03451292)
- Testing
- Albutein 20%, SMT
- Where
- 66 sites in United States, Belgium and 12 more
- Volunteers
- 410 people
- Sponsor
- Grifols Therapeutics LLC
Cirrhosis, Acute Decompensation
Study of microRNAs in a Decompensated Cirrhosis
Cirrhotic patients are at higher risk of sepsis due to impaired innate and adaptive immune responses. Septic complications represent a major issue in the management of cirrhotic patients, with a 1-month mortality rate of 23%…
- Trial name
- EmiC (NCT03905746)
- Testing
- blood sample at Day 0, blood sample at Day 2 and Day 7, stool sample at Day 0
- Where
- France
- Volunteers
- 444 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis B, Hepatitis C
A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis
Cirrhosis is a diffuse lesion characterized by architectural distortion of the liver because of collagen deposition and development of nodules of regenerating hepatocytes.
- Conditions
- Hepatitis B, Hepatitis C, Liver Cirrhosis
- Trial name
- NCT00562783
- Testing
- Vitaliver
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hospital Authority, Hong Kong
Liver Cirrhosis, Malnutrition
Establishment of a Model for Predicting the Prognosis of HBV-related Decompensated Liver Cirrhosis Based on RFH-NPT
For all countries, chronic liver disease and liver cirrhosis is one of the important disease burdens. Malnutrition is an important complication of liver cirrhosis, which always runs through the course of liver cirrhosis.
- Trial name
- NCT05513651
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
HCV Related Cirrhosis
To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis
In this prospective randomized trial, A Minimum of 300 consecutive patients of decompensated HCV (Hepatitis C Virus) related cirrhosis, presenting to the Institute of Liver and Biliary Sciences hospital will be included and those…
- Trial name
- NCT02464631
- Testing
- Sofosbuvir + Ribavirin 1, Sofosbuvir + Ribavirin 2, Sofosbuvir + Ribavirin 3
- Where
- India
- Volunteers
- 62 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis
Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis
Disorders of glucose metabolism, such as impaired glucose intolerance (IGT) and diabetes mellitus (DM), frequently occur in cirrhosis. However, it has been underestimated when fasting plasma glucose (FPG) levels are considered.
- Trial name
- NCT04828512
- Volunteers
- 1,015 people
- Sponsor
- Yonsei University
Decompensated Cirrhosis Ethanol Related
Effect of Whey Protein Versus Egg Albumen Protein Challenge on Blood Ammonia Level in Patients of Decompensated Ethanol Related Cirrhosis.
In cirrhosis, altered nitrogen metabolism and reduced hepatic clearance of ammonia contribute to the development of Minimal Hepatic Encephalopathy (MHE)-a subclinical but functionally debilitating condition.
- Trial name
- NCT07299110
- Testing
- Whey Protein, Egg Albumen
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis
To Develop and Validate an Equation for Determination of Major Adverse Kidney Events in Patients With Decompensated Cirrhosis and Ascites.
Acute kidney injury (AKI) is the sudden loss of kidney function that occurs frequently in hospitalised patients with cirrhosis. It develops in up to 53% and is independently associated with high short-term mortality.
- Trial name
- NCT07794787
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis
A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.
This will be a randomized double blind study which will be conducted on patients admitted to Department of Hepatology from June 2013 to may 2014 at ILBS, New Delhi.
- Trial name
- NCT01902511
- Testing
- G-CSF+Erythropoetin, G-CSF
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Training and Validation Data Collection Study
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD TVDCS (NCT06675604)
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 4,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Decompensated Cirrhosis, Portal Hypertension
The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS
The aim of this study is to evaluate the effectiveness of L-ornithine-L-aspartate (LOLA) on plasma ammonia in cirrhotic patients after Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure.
- Conditions
- Decompensated Cirrhosis, Portal Hypertension, Bleeding Varices, Refractory Ascites
- Trial name
- NCT01440829
- Testing
- L-ornithine-L-aspartate
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Air Force Military Medical University, China
Cirrhosis
Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9
Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease.
- Trial name
- NCT07652203
- Testing
- conventional therapy, propranolol
- Where
- China
- Volunteers
- 466 people
- Sponsor
- General Hospital of Shenyang Military Region
Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores.
- Trial name
- NCT07002827
- Testing
- Darbepoetin, G-CSF, Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis
Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis
There has been great interest in recent years to take advantage of stem cells to treat liver cirrhosis. Mesenchymal stem cells (MSC) has been shown to be safe and effective for liver diseases in some studies.
- Trial name
- NCT03209986
- Testing
- mesenchymal stem cell transplantation via peripheral vein, mesenchymal stem cell
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Decompensated Cirrhosis
Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status
The aim of this study is to investigate the effect of albumin infusion on oxidative albumin modification, on plasma thiol status and on albumin binding capacity for DS in patients who routinely receive albumin infusion for…
- Trial name
- ALB-INFUS (NCT03214796)
- Testing
- Human albumin
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Graz
Paracentesis-Induced Circulatory Dysfunction
Low-dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis (LVP) in Decompensated Cirrhosis Liver.
Abstract for thesis protocol. Background: Paracentesis induced circulatory dysfunction (PICD) is a common complication of large volume paracentesis in cirrhotic patients, which can lead to renal impairment, hyponatremia, and…
- Trial name
- PICD LVP (NCT06892535)
- Testing
- Albumin infusion, 2g/L of ascitic fluid aspiration.
- Where
- Bangladesh
- Volunteers
- 52 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Decompensated Cirrhosis
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural…
- Trial name
- NC-CHRM (NCT07131280)
- Testing
- Gcsf, Darbepoetin, Standard Medical Treatment
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Liver Cirrhosis
A Study of ADR-001 in Patients With Liver Cirrhosis
This is a first-in-human Phase1/2 study of ADR-001, adipose-derived mesenchymal stem cells (AD-MSCs). The safety and preliminary efficacy are evaluated in Phase 1 in patients with liver cirrhosis caused by Hepatitis C or…
- Trial name
- NCT03254758
- Testing
- Mesenchymal stem cell
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
Hepatic Impairment, Cirrhosis
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of…
- Trial name
- NCT05484206
- Testing
- VIR-2218, VIR-3434
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.